APA (7th ed.) Citation

Georgy, J. T., Regi, S. S., Georgy, R. V., Sasidharan, B. K., Joel, A., Philip, D. S. J., . . . Singh, A. (2025). Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy. Scientific Reports, 15(1), 1. https://doi.org/10.1038/s41598-025-19197-y

Chicago Style (17th ed.) Citation

Georgy, Josh Thomas, et al. "Low-dose Nivolumab Plus Induction Chemotherapy for Locally Advanced or Unresectable Head and Neck Cancer Is Associated with High Response Rates and Conversion to Definitive Therapy." Scientific Reports 15, no. 1 (2025): 1. https://doi.org/10.1038/s41598-025-19197-y.

MLA (9th ed.) Citation

Georgy, Josh Thomas, et al. "Low-dose Nivolumab Plus Induction Chemotherapy for Locally Advanced or Unresectable Head and Neck Cancer Is Associated with High Response Rates and Conversion to Definitive Therapy." Scientific Reports, vol. 15, no. 1, 2025, p. 1, https://doi.org/10.1038/s41598-025-19197-y.